36Kr learned that Shenzhen Aibo Medical Robot Co., Ltd. (referred to as Aibo Medical Robot), which specializes in the research and development of vascular interventional surgery robots, has completed the Pre-A financing of 12 million yuan. This round of financing was jointly led by CDH VGC (Innovation and Growth Fund) and Yahui Investment, followed by private capital from Chang 'an, and Changling Capital, the investor led by Angel Wheel, continued to invest in excess. This round of financing will be used to promote the clinical registration of the company's vascular interventional surgery robot products, strengthen team building and accelerate product development.
aibo medical robot was established in Shenzhen in June 22, focusing on the market of vascular interventional surgery robots. It is reported that behind this "new" company are years of scientific research and technology precipitation-that is, the research and development accumulation of the founding team led by Academician Guo Shuxiang and Dr. Guo Jian for nearly 3 years, and the corresponding patent matrix.
It is reported that as early as 28, the founder of the company, Academician Guo Shuxiang, pioneered the development of the world's first panvascular interventional surgery robot in Japan, which can be used for angiography and treatment of nerves, coronary arteries and peripheral blood vessels; In 217, the prototype of vascular interventional surgery robot developed by the company team completed the first domestic clinical trial of nerve interventional surgery in Beijing Tiantan Hospital; Up to now, the vascular interventional surgery robot of Aibo Medical Robot has been iterated to the third generation.
According to the person in charge of Aibo Medical Robot, the company's vascular interventional surgery robot is improving towards miniaturization, light weight and low cost. This year, the vascular interventional surgery robot of Aibo Medical Robot is expected to enter the registered clinical stage.
In recent years, the number of vascular interventional operations in China has increased, which has gradually exposed some problems such as the shortage of medical resources and the uneven distribution of doctors and patients. Taking nerve intervention as an example, nerve intervention is called the jewel in the crown of interventional surgery, which has the characteristics of great difficulty, high risk and long time. The cerebral vessels are fragile, the precision of interventional operation is high, and it is highly dependent on the personal experience and level of doctors. The time required for a neurointerventional operation may be more than twice as long as that for a coronary interventional operation, and the training period of doctors is long, and the corresponding workload is heavy. The emergence of surgical robots makes it possible to be intelligent and automatic in vascular interventional surgery, and acts as the eyes, hands and brain of doctors.
Based on the huge market demand, the market size of vascular interventional surgical robots in China will reach RMB 34 million in 222, and further increase to RMB 5.824 billion in 23, with a compound annual growth rate of 9.3% from 222 to 23.
The person in charge of Aibo Medical Robot said: "Compared with laparoscopy or orthopedics, vascular intervention is an easier and more automated surgical scene. Vascular interventional surgery robots operate in blood vessels, just like self-driving cars driving on highways. " It is reported that through the mode of master-slave separation and based on accurate force feedback, medical personnel can use the vascular interventional surgery robot of Aibo Medical Robot to perform surgery outside the catheter, which not only makes the interventional surgery more accurate and efficient, but also reduces the incidence of postoperative complications of patients, and keeps doctors away from the catheter room and reduces radiation.
According to reports, at present, most vascular interventional surgery robots on the market have a single function and can only meet the function of pushing guide wires. However, in vascular interventional surgery, especially in nerve intervention, doctors usually need to operate a variety of guide wires to carry out surgery, and during the operation, they need to operate the catheters for multiple angiography to observe the position of the instruments and the blood vessels. Because it is impossible to realize the cooperative operation of multiple instruments, the existing vascular interventional surgery robots are not widely compatible with all kinds of vascular interventional surgery, including angiography and treatment, and play a role in the operation for a short time. At the same time, they need bedside teamwork, so doctors can't really avoid exposure to radiation.
Therefore, Aibo Medical Robot designs a vascular interventional surgery robot based on the modular concept, which can satisfy the cooperative operation control of multi-catheter guide wires, complete the composite actions such as pushing, rotating, pushing+rotating, etc. The product is compatible with all kinds of standardized guide wires in the market, and adapts to various surgical procedures, including nerve intervention, coronary intervention, peripheral intervention and so on, and can be regarded as a "pan-vascular interventional surgery robot". It is reported that these operations "will involve more than 5 million domestic operations in the future". At present, Aibo Medical Robot has established close cooperation with well-known hospitals such as Shanghai Changhai Hospital, Shanghai Zhongshan Hospital, Huazhong University of Science and Technology and Shenzhen Hospital, and wants to find the real pain points and needs in clinic through the mode of combining medical care with work.
From the supply side, the global market for vascular interventional surgery robots is still in the early stage of development. At present, only three products have been approved, and there is no vascular interventional surgery robot approved in China, which has a certain market access window. Nowadays, a number of innovative enterprises at home and abroad have begun to flood into the robot track of vascular interventional surgery, such as Weimai Medical, Aopeng Medical, Minimally Invasive Robot, Ruixin Medical, etc., and began to fight for technology, team and products. Unlike the endoscopic surgery robot market where Leonardo da Vinci's surgical robots occupy half of the country, the market pattern of vascular interventional surgery robots is uncertain.
In p>221, it will attract nearly 1 billion yuan. Is vascular intervention the next dark horse for surgical robots? | 36Kr New Wind Direction